<DOC>
	<DOC>NCT01272817</DOC>
	<brief_summary>Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative syndromes, lymphoma, or myeloma using a nonmyeloablative preparative regimen.</brief_summary>
	<brief_title>Nonmyeloablative Allogeneic Transplant</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Anemia, Aplastic</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1. Age &gt; 55 years or 2. Age &lt; 55 and LVEF &lt; 45% or creatinine clearance &lt; 60 ml/min 3. Ability to cover the cost of the transplant, necessary medications, and transportation/housing. 4. Caregiver must be available while outpatient Guidelines for CladribineMelphalanbased conditioning: Bone Marrow Failure States Severe Aplastic Anemia (relapsed following immunosuppressive therapy) Paroxysmal Nocturnal Hemoglobinuria (poor prognostic features or hemosiderosis) AML (first CR except for t(15;17), inv16, t(8,21); second CR; relapse failing second induction attempt) ALL (first CR with at least one poor prognostic feature; second or greater CR; relapse failing reinduction attempt) MDS (RAEB, RAEBiT, CMMoL) CML (chronic phase; accelerated phase; blast phase following reinduction attempt; 2nd chronic or accelerated phase following gleevec therapy Hodgkin's lymphoma (first or greater relapse) NonHodgkin's Lymphoma Aggressive Histology (includes T Cell NHL) Incomplete response to induction Second CR Sensitive or refractory relapse Indolent Histology Second or greater relapse Mantle Cell Lymphoma (any Stage must have received induction chemotherapy) Multiple Myeloma (10% residual plasmacytosis following anthracyclinebased chemotherapy or residual disease following autologous transplant) Waldenstrom Macroglobulinemia (must have failed either purine analoguebased chemotherapy (Fludara or 2CdA) or standard CVP therapy; hyperviscosity or cytopenias) Guidelines for total lymphoid irradiationbased conditioning MDS (RA, RARS) CLL (Rai stage III or IV must have received at least two different treatment regimens in the past) Breast Cancer (symptomatic metastatic disease, who have failed standard chemotherapy) Renal Cell Cancer (metastatic disease at multiple sites) Malignant Melanoma (metastatic disease at multiple sites) Sarcoma (all subtypes presently, unresectable metastatic disease) Ovarian Cancer (stage III or IV, platinum insensitive disease, i.e. progression within 6 months of initial platinum chemotherapy) Thymoma (unresectable disease) 1. Prior allogeneic stem cell or bone marrow transplant 2. Current or past history of invasive mycotic infection 3. Breast Feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Nonmyeloablative transplant</keyword>
	<keyword>Allogeneic transplant</keyword>
	<keyword>Transplant</keyword>
</DOC>